John Solomon joined Sanofi in 2005 as the Head of Pharmacovigilance at the UK Affiliate with
responsibility for pre/post authorisation drug surveillance activities for a large portfolio of medicines covering Sanofi’ s [branded, cosmetics, medical devices], Zentiva’s[generics] and Genzyme’s[ biologics].
Qualified in medicine, John has worked for over 16 years in the industry spending the last 12 of these years in clinical drug safety and post marketing drug surveillance activities.
Other industry related experience includes pharmaceutical marketing and managing global
clinical-drug safety programmes in the Pharmaceutical industry and CRO sectors respectively.
John has over the years interfaced with UK Regulators on various Agency/industry initiatives
including the Pharmacovigilance (PV) Better Regulation of Medicines Initiative (BROMI) work
stream in the UK, the lay summary “Risk Management Plan”, Forum on Benefit-Risk decision
analysis and the implementation of the New Pharmacovigilance legislation.
John is currently an industry representative on various UK Trade-associations Pharmacovigilance networks.
John is especially committed to transparency around patient centric Pharmacovigilance and the commercial value of effective Pharmacovigilance.